N/A
N=11
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
Huntington's Disease
Bottom Line
View on ClinicalTrials.gov: NCT01451463 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Oct 2017
Primary outcome: Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ohio State University
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tinetti Mobility Test Score |
19.91; 17.09 | — |
| SECONDARY Five Times Sit to Stand Test |
12.61; 15.52 | .009 sig |
Summary
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates. Xenazine (tetrabenazine) is a monoamine-depleting drug that is commonly used to reduce chorea.
The purpose of this study is to compare: 1) spatial and temporal gait measures, 2) performance on functional mobility measures, and 3) amount of daily walking activity before and after administration of Xenazine in individuals with HD. It is hypothesized that the use of Xenazine to decrease chorea will improve functions of 1) gait, 2) sit-to-stand transfers 3) stair climbing and 4) overall daily physical activity and function.
Eligibility Criteria
Inclusion Criteria
- Huntington's Disease
- Able to ambulate independently
Exclusion Criteria
- Other orthopedic or neurological disorder that affects gait or balance
- Pregnancy
- Chorea score <10 prior to initiation of medication.
- Inability to provide informed consent
Data sourced from ClinicalTrials.gov (NCT01451463). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.